Sofosbuvir/Ledipasvir ± Ribavirin Effectively Treats HCV After Liver, Renal Transplantation
Treatment of HCV with sofosbuvir/ledipasvir ± ribavirin after liver or renal transplantation is safe and effective.
Treatment of hepatitis C virus (HCV) after liver or renal transplantation with sofosbuvir (SOF)/ledipasvir (LDV) ± ribavirin (RBV) is safe and effective, according to a study published in SAGE Open Medicine.
Researchers in Turkey evaluated 12 patients who had undergone renal transplantation and 11 patients who had undergone liver transplantation, all of whom received SOF/LDV ± RBV over 12 or 24 weeks.
All of those who underwent renal transplant and all but one of those who underwent liver transplant had HCV genotype 1. The researchers found that end-of-treatment virologic response and sustained virologic response at 12 weeks ratios were 100% in both groups in patients who received SOF/LDV with RBV or SOF/LDV without RBV for 12 or 24 weeks.
No adverse effects led to discontinuation of treatment and no significant changes in mean creatinine, estimated glomerular filtration rate, or bilirubin levels occurred during treatment.
Nine of those who underwent renal transplant and all of those who underwent liver transplant received tacrolimus, but no significant changes in tacrolimus levels occurred during treatment.
Two of those who underwent renal transplant were treated with cyclosporine and 1 patient in each group received everolimus. No changes occurred that caused a significant dose modification in serum cyclosporine and everolimus levels in these patients.
“In conclusion, according to the large-scale literature data and the results of our study, SOF/LDV ± RBV is quite effective in liver and/or renal transplant patients with chronic HCV,” stated the authors.
Akin M, Buldukoglu OC, Adanir H, Suleymanlar I, Dincer D, Yildirim B. Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience [published online June 5, 2018]. SAGE Open Med. doi: 10.1177/2050312118781416